North America
Foundation Medicine Test Nabs FDA Approval as CDx for BRAF Inhibitor Therapeutics for Melanoma
FoundationOneCDx will also automatically be a companion diagnostic for future BRAF inhibitors approved by the FDA that target specific BRAF mutations.
Pan-Cancer Analysis Reveals Unique Features in Tumors From Younger People
Tumors in younger individuals exhibited a dysregulated molecular aging phenotype and were associated with hallmarks of premature senescence.
Spectrum Pharmaceuticals Seeking FDA Approval for Poziotinib as Lung Cancer Treatment
The new drug application contains data from the ZENITH20 trial, demonstrating the drug's activity in NSCLC patients with HER2 exon 20 insertion mutations.
Freenome Raises $300M in Series D Financing
The company will use the funding to support commercialization of its blood-based colorectal cancer detection test and to fuel expansion to other tumor types.
NGM Biopharmaceuticals, Merck to Study ILT2/4 Inhibitor Plus Keytruda in Solid Tumors
The companies inked a collaboration to study the drug combination in advanced solid tumors with elevated expression of ILT2 and ILT4.